Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 8/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247149 | 0.83 | BRD4 (0.36) | BRD4KDM4EALDH1A1SMN1; SMN2PGR | |
| SCHEMBL4677149 | 0.83 | BRD4 (0.38) | BRD4KDM4EALDH1A1SMN1; SMN2PGR | |
| SCHEMBL16792615 | 0.81 | TGM2 (0.33) | BRD4TGM2 | |
| SCHEMBL30753011 | 0.80 | PGR (0.40) | BRD4KDM4EALDH1A1SMN1; SMN2PGR | |
| SCHEMBL15337460 | 0.80 | PGR (0.40) | BRD4KDM4EALDH1A1SMN1; SMN2PGR | |
| SCHEMBL16792465 | 0.76 | PDK2 (0.38) | BRD4KDM4EALDH1A1SMN1; SMN2PGR | |
| SCHEMBL29622749 | 0.72 | KDM4E (0.55) | BRD4KDM4EALDH1A1SMN1; SMN2PGR | |
| SCHEMBL754728 | 0.70 | BRD4 (0.38) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL31694125 | 0.70 | BRD4 (0.46) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL16893998 | 0.70 | BRD4 (0.46) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080115-B1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-05-08 | — | — | EP | disclosed |
| US-9868749-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-16 | — | — | US | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | BRD4 811/4885KDM4E 4278/4885ALDH1A1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.